Skip to main content
Alzheimer's & Dementia logoLink to Alzheimer's & Dementia
. 2026 Jan 8;21(Suppl 2):e107124. doi: 10.1002/alz70856_107124

Every Centiloid, from Everywhere, All at Once

Ganna Blazhenets 1,, Heather M Snyder 2, Liana G Apostolova 3, Breton M Asken 4, Alexandre Bejanin 5,6, Stéphanie Bombois 7, Pierrick Bourgeat 8, Meredith N Braskie 9, Maria C Carrillo 2, Kaitlin B Casaletto 10, David M Cash 11, Chiung‐Chih Chang 12,13, Hsin‐I Chang 12, Yishu Chao 14, Gael Chételat 15, William Coath 11, Lyduine E Collij 16,17, Lise Colmant 18, Brad C Dickerson 19, Bruno Dubois 7, Alfonso Fajardo Valdez 20, Gill Farrar 21, Juan Fortea 5, Giovanni B Frisoni 22,23, Raquel C Gardner 24, Valentina Garibotto 25,26,27, Yuna Gu 28, Tengfei Guo 29, Bernard J Hanseeuw 18, Oskar Hansson 30, Theresa M Harrison 31, Qi Huang 32, Shu‐Hua Huang 33, Kazunari Ishii 34, Kenji Ishii 35, William J Jagust 31, Takashi Kato 36, Robert A Koeppe 37, Joel H Kramer 10, Susan M Landau 31, Brigitte Landeau 15, Sangwon Lee 38, Brian J Lopresti 39, Val J Lowe 40, Xiaoxie Mao 32, Andrew March 41, Colin L Masters 8, Florence Mézenge 15, Elizabeth C Mormino 42, Maria Franquesa‐Mullerat 5, Akinori Nakamura 36, Sid E O'Bryant 43, Ioannis Pappas 44, Débora E Peretti 27, Lisa Quenon 18, Christopher C Rowe 8, Gemma Salvadó 45, Jonathan M Schott 11, Daniel Schwartz 46, Christopher G Schwarz 40, Sang Won Seo 47, Mahnaz Shekari 45, Lisa C Silbert 46, Ruben Smith 17, Andrzej Sokolowski 42, David N Soleimani‐Meigooni 1, Reisa A Sperling 19, Pan Sun 29, Arthur W Toga 48, David E Vaillancourt 49, Elsmarieke van de Giessen 16, Wiesje M van der Flier 16, Prashanthi Vemuri 40, Nicolas Villain 7, Victor L Villemagne 50, Sylvia Villeneuve 20, Wei‐En Wang 49, Michael S W Weiner 1, Cally Xiao 44, Fang Xie 32, Yeojun Yoon 38, Christina B Young 42, Mijin Yun 38, Gil D Rabinovici 1, Renaud La Joie 1; AMYPAD and LEADS Consortia
PMCID: PMC12782801

Abstract

Background

Ten years after the original publication, the Centiloid framework is now broadly used to harmonize amyloid‐PET quantification, facilitate data sharing and comparison across cohorts, and even assist visual interpretation in clinical settings. We evaluated the global implementation of Centiloids by comparing their distribution and corresponding positivity thresholds across cohorts.

Methods

We gathered data from publicly available cohorts and reached out to investigators across the world to collect cross‐sectional Centiloids, demographic and clinical information, and visual read data. Gaussian mixture models (GMM, k=2) were fitted to Centiloid values for each cohort and cutoffs were calculated as mean + 2SD of the lower Gaussian. When visual reads were available, we determined Centiloid cutoffs that maximized correspondence with visual reads (Cohen's kappa). Data was combined across cohorts using random effects meta‐analyses.

Results

As of January 2025, we included 37 cohorts (n = 41,678 participants) with heterogeneous pipelines, radiotracers, and clinical and demographic characteristics (Table‐1). The low Gaussian peaks ranged from ‐9 to 10CL; the meta‐analysis identified a common peak at 1CL. The second peaks were more heterogeneous (range=38‐102CL; meta‐analysis outcome=64CL). Across cohorts, the proportion of cognitively unimpaired versus impaired participants impacted the position of both peaks, with better separation in cohorts enriched in impaired individuals (Figure 1C). The meta‐analysis indicated a GMM‐based cutoff of 19CL (95%CI: 16‐21CL, Figure 1B); subgroup analyses showed no evidence of significant effect between single versus multicenter settings (17 versus 20CL, p = 0.30), MRI‐based or PET‐only processing (18 versus 19CL, p = 0.88), and no evidence of difference across radiotracers (Flutemetamol: 16CL; PIB: 17CL, Flutafuranol: 18CL, Florbetaben: 19CL, Florbetapir: 20CL, p = 0.78). In a subset of 29,496 participants with visual reads available, binary visual reads corresponded well to Centiloids (common kappa=0.86, Figure 2A). The visual read‐based cutoff of 24CL (95%CI: 21‐27CL, Figure 2B) maximized correspondence between visual read and quantification and was slightly higher than the GMM‐based cutoff. All meta‐analysis models showed high non‐random heterogeneity (I2>80%) across studies, suggesting non‐random differences in peaks and cutoffs.

Conclusions

Meta‐analysis‐based cutoffs align well with thresholds from the existing literature. High heterogeneity among studies underscores the need to investigate contributing factors, raising concerns about applying common cutoffs.


graphic file with name ALZ-21-e107124-g003.jpg

graphic file with name ALZ-21-e107124-g002.jpg

graphic file with name ALZ-21-e107124-g001.jpg


Articles from Alzheimer's & Dementia are provided here courtesy of Wiley

RESOURCES